Libero Santarpia
Pfizer (United States)(US)
Publications by Year
Research Areas
MicroRNA in disease regulation, Circular RNAs in diseases, Cancer-related molecular mechanisms research, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy(2012)1,025 cited
- → miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients(2016)810 cited
- → Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients(2011)287 cited
- → Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis(2021)256 cited
- → Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer(2010)230 cited
- → A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients(2014)227 cited
- → Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer(2007)206 cited
- → Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes(2015)200 cited
- → Targeting microRNAs as key modulators of tumor immune response(2016)192 cited
- → Missense Mutation in the Transcription Factor NKX2–5: A Novel Molecular Event in the Pathogenesis of Thyroid Dysgenesis(2006)180 cited